相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer
Laura Evangelista et al.
EUROPEAN UROLOGY FOCUS (2020)
Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [18F]DCFPyL PET/CT
Yafu Yin et al.
MOLECULAR IMAGING AND BIOLOGY (2019)
PET imaging in renal cancer
Liza Lindenberg et al.
CURRENT OPINION IN ONCOLOGY (2019)
177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
Yongchang Lai et al.
CANCER CELL INTERNATIONAL (2018)
Targeting PSMA by radioligands in non-prostate disease-current status and future perspectives
Philipp Backhaus et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2018)
Recurrent renal cell carcinoma following nephrectomy and ablation therapy: Radiology perspective
Osama Ali et al.
EUROPEAN JOURNAL OF RADIOLOGY (2018)
Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy
F. Stephen Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Potential use of prostate specific membrane antigen (PSMA) for detecting the tumor neovasculature of brain tumors by PET imaging with 89Zr-Df-IAB2M anti-PSMA minibody
Masahide Matsuda et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role
Sophia Spatz et al.
JOURNAL OF UROLOGY (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience
Lino M. Sawicki et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2017)
PSMA-Targeted 18F-DCFPyL PET/CT Imaging of Clear Cell Renal Cell Carcinoma: Results from a Rapid Autopsy
Michael A. Gorin et al.
EUROPEAN UROLOGY (2017)
Utility of 68Ga prostate specific membrane antigen - positron emission tomography in diagnosis and response assessment of recurrent renal cell carcinoma
Shankar Siva et al.
JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
PSMA: a potential therapeutic target in RCC
Michael A. Gorin et al.
NATURE REVIEWS UROLOGY (2017)
Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2017)
Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease
Nina Wagener et al.
PLOS ONE (2017)
Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine
Atul B. Shinagare et al.
RADIOLOGY (2017)
Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey
Katarina Sjogreen Gleisner et al.
EJNMMI PHYSICS (2017)
Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force
Caroline Stokke et al.
EJNMMI PHYSICS (2017)
Use of DWI in the Differentiation of Renal Cortical Tumors
Andreas M. Hoetker et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2016)
Prostate-specific membrane antigen (PSMA)-mediated laminin proteolysis generates a pro-angiogenic peptide
Rebecca E. Conway et al.
ANGIOGENESIS (2016)
68Ga Prostate-Specific Membrane Antigen Uptake in Renal Cell Cancer Lymph Node Metastases
Ingo Einspieler et al.
CLINICAL NUCLEAR MEDICINE (2016)
Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma
Arun Sasikumar et al.
CLINICAL NUCLEAR MEDICINE (2016)
Detection of F-18-FDG PET/CT Occult Lesions With F-18-DCFPyL PET/CT in a Patient With Metastatic Renal Cell Carcinoma
Steven P. Rowe et al.
CLINICAL NUCLEAR MEDICINE (2016)
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri et al.
LANCET ONCOLOGY (2016)
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
W. Marston Linehan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Radiolabeled enzyme inhibitors and binding agents targeting PSMA: Effective theranostic tools for imaging and therapy of prostate cancer
Maroor Raghavan Ambikalmajan Pillai et al.
NUCLEAR MEDICINE AND BIOLOGY (2016)
Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour
Handoo Rhee et al.
EJNMMI RESEARCH (2016)
Renal cell carcinoma: staging and surveillance
N. Reed Dunnick
ABDOMINAL RADIOLOGY (2016)
Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT
Steven P. Rowe et al.
ANNALS OF NUCLEAR MEDICINE (2015)
Multiparametric MRI of solid renal masses: pearls and pitfalls
N. K. Ramamurthy et al.
CLINICAL RADIOLOGY (2015)
EAU Guidelines on Renal Cell Carcinoma: 2014 Update
Borje Ljungberg et al.
EUROPEAN UROLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Preoperatively Misclassified, Surgically Removed Benign Renal Masses: A Systematic Review of Surgical Series and United States Population Level Burden Estimate
David C. Johnson et al.
JOURNAL OF UROLOGY (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
68Ga-PSMA PET/CT imaging of metastatic clear cell renal cell carcinoma
Emre Demirci et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2014)
Alternative Response Criteria (Choi, European Association for the Study of the Liver, and Modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib
Maxime Ronot et al.
ONCOLOGIST (2014)
The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma
Carmelo Caldarella et al.
RADIOLOGY AND ONCOLOGY (2014)
Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2
Rebecca E. Conway et al.
ANGIOGENESIS (2013)
Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy
N. S. Vasudev et al.
BRITISH JOURNAL OF CANCER (2013)
Differentiating mTOR inhibitors in renal cell carcinoma
Sumanta K. Pal et al.
CANCER TREATMENT REVIEWS (2013)
Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements
Mizuki Nishino et al.
CLINICAL CANCER RESEARCH (2013)
Multiphasic Enhancement Patterns of Small Renal Masses (≤4 cm) on Preoperative Computed Tomography: Utility for Distinguishing Subtypes of Renal Cell Carcinoma, Angiomyolipoma, and Oncocytoma
Phillip M. Pierorazio et al.
UROLOGY (2013)
Distribution of metastatic sites in renal cell carcinoma: a population-based analysis
M. Bianchi et al.
ANNALS OF ONCOLOGY (2012)
68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
Matthias Eder et al.
BIOCONJUGATE CHEMISTRY (2012)
Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
C. Barinka et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Oncologic applications of diffusion-weighted MRI in the body
Susanne Bonekamp et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2012)
Angiomyolipoma with Minimal Fat: Can It Be Differentiated from Clear Cell Renal Cell Carcinoma by Using Standard MR Techniques?
Nicole Hindman et al.
RADIOLOGY (2012)
Skeletal complications and survival in renal cancer patients with bone metastases
Emma Woodward et al.
BONE (2011)
2-(3-{1-Carboxy-5-[(6-[18F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
Ying Chen et al.
CLINICAL CANCER RESEARCH (2011)
Lymph Node Dissection in Renal Cell Carcinoma
Umberto Capitanio et al.
EUROPEAN UROLOGY (2011)
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
Brian I. Rini et al.
LANCET (2011)
Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Clinical Evidence
Thomas E. Hutson
ONCOLOGIST (2011)
Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
Cora N. Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Radical Nephrectomy with and without Lymph-Node Dissection: Final Results of European Organization for Research and Treatment of Cancer (EORTC) Randomized Phase 3 Trial 30881
Jan H. M. Blom et al.
EUROPEAN UROLOGY (2009)
N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC:: A new imaging probe for prostate cancer
Ronnie C. Mease et al.
CLINICAL CANCER RESEARCH (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
Bernard Escudier et al.
LANCET (2007)
Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms
Angelo Baccala et al.
UROLOGY (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria
Haesun Choi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
Robert J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction
Rebecca E. Conway et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
Expression of prostate-specific membrane antigen in normal and malignant human tissues
Y Kinoshita et al.
WORLD JOURNAL OF SURGERY (2006)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Treatment of osseous metastases in patients with renal cell carcinoma
ST Jung et al.
CLINICAL ORTHOPAEDICS AND RELATED RESEARCH (2003)
分享论文
